Cerebral palsy: A unique illustrated experience

Cerebral palsy: A unique illustrated experience

  • Aamir Jalal Al-Mosawi Baghdad Medical City and the National Center of Training and Development Baghdad, Iraq
Keywords: Cerebral palsy, multi-factorial therapies, illustrative experience

Abstract

Background: Cerebral palsy is a heterogeneous condition associated with a non-progressive lesion causing permanent disorder of movement with limited mobility, and is generally associated with gross motor developmental delay. In moderate to severe cases of cerebral palsy, motor developmental milestones such as walking may never be achieved. Impaired cognition and delayed speech are also common. 

Patients and methods: Seventeen patients with cerebral palsy are described in this paper including two female patients whose early treatment courses were included in previous publications, and 15 new cases (11 males and 4 females) observed during seven months period (May-November,2019). Their ages ranged from 10 months to 9 years. Ten patients had significant spasticity limiting their movements. All patients had developmental delays including delayed speech. Nine patients were unable to sit without support, including a patient with significant dystonia, and a patient who could stand and walk with support but was unable to sit without support. Only two patients were able to walk alone, but slowly and with difficulty. Two patients had history of birth asphyxia, and one patient had a genetic condition with 2 of his brothers being affected. The patients were treated based on our published experiences with individualized treatment plans providing a combination of various interventions including nutritional support, muscle relaxants, oral pyritinol, intramuscular piracetam, citicoline (oral and injectable), intramuscular cerebrolysin, and intramuscular nandrolone decanoate. The aims of these therapies include overcoming spasticity, repairing the brain and improving its function, and ultimately improving mobility and advancing development. 

Results: All patients experienced improvement in motor development without the occurrence of any side effect. However, it was not possible to document the details of treatments and follow-up for all patients, but it was possible to provide an illustrated demonstration of improvement in seven patients. 

Conclusion: Cerebral palsy is a heterogeneous condition, and the emergence of a single therapeutic agent that offers a comprehensive effect to improve its manifestations is very unlikely is the near future. Therefore, the use of evidence-based multi-factorial therapies is advisable. Adequate muscle relaxation is vital to prevent the complications of contractures which appear to cause a progressive disability.

Downloads

Download data is not yet available.

References

-Al Mosawi AJ. Dramatic effect of nandrolone decanoate on motor development in cerebral palsy. Arch Dis Child 2008; 93(11) : (Suppl II): A338-A339.

-Al Mosawi AJ. A novel therapeutic approach for the treatment of cerebral palsy (Ed). LAP Lambert Academic Publishing, Germany, 2017.

-Al Mosawi AJ. A novel therapeutic approach for the treatment of brain atrophy (Ed). LAP Lambert Academic Publishing, Germany, 2017.

-Al Mosawi AJ. New therapies for the treatment of spastic cerebral palsy (Ed). LAP Lambert Academic Publishing, Germany, 2019.

-Al-Mosawi AJ. New therapies for the treatment of spastic cerebral palsy. Med J Clin Trials Case Stud (ISSN: 2578-4838) 2019; 3(2): 000209. USA. DOI: 10.23880/mjccs-16000209

-Al-Mosawi AJ. The pattern of cerebral palsy in Iraqi children. Med Life Clin. 2019; 1(1):1001.

-Al-Mosawi AJ. The pattern of cerebral palsy in Iraqi children. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-620-0-09427-8).

-Al-Mosawi AJ. Citicoline research progress. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-620-0-11372-6).

-Al-Mosawi AJ. The use of citicoline in pediatric neurology and pediatric psychiatry. Austin Pediatrics (ISSN: 2381-8999) 2019; 6(1): 1071-1072.

-Al-Mosawi AJ. The use of cerebrolysin and citicoline in autism and Asperger syndrome. J Bio Innov 2019; 8(1): 99-108.

-Al-Mosawi AJ. New therapies for Rett syndrome. J Bio Innov 2019; 8(3): 301-307.

-Al-Mosawi AJ. A new therapeutic approach for pervasive developmental disorders. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018(ISBN: 978-3-659-86602-9).

-Al-Mosawi AJ. Pervasive developmental disorders in Iraqi children. Journal of Psychiatry Research Reviews & Reports 2019; 1(1): 1-8.

-Al-Mosawi AJ. The pattern of pervasive developmental disorders in Iraqi children.1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-3-330-05029-7).

-Al-Mosawi AJ. Our experience with childhood pervasive developmental disorders (Autism and Asperger Syndrome): Cure is Possible. EC Clinical and Medical Case Reports 2020; 3(4): 01-08. Doi: 10.5281/zenodo.3892198

-Al-Mosawi AJ. Autism disorders: Cure is possible. 1st ed., Saarbrücken; LAP Lambert Academic Publishing, Saarbrücken; Germany, 2020 (ISBN-13:978-620-2-66617-6, ISBN-10: 620266617X).

-Al-Mosawi AJ. Cure of autistic disorders: Our unique experience .1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2020 (ISBN: 978-620-2-67716-5).

-Al-Mosawi AJ. The treatment of a child with birth asphyxia induced brain atrophy, adrenal hemorrhage, and bi-lateral hyperoxaluric nephrocalcinosis: A challenging case and unique experience. Open Access Journal of Biogeneric Science and Research (ISSN: 2692-1081) 2020; 2(2): 1-6. 29/06/2020. DOI: 10.46718/JBGSR.2020.01.000043

-Al-Mosawi AJ. The novel use of cerebrolysin and citicoline in the treatment of kernicterus. Online Journal of Neurology and Brain Disorders (ISSN: 2637-6628) 2019; 3 (1): 208-212. DOI: 10.32474/OJNBD.2019.03.000151.

-Al-Mosawi AJ. Recent uses of piracetam in pediatric neurology. SunKrist Neurology, Neurosurgery and Stroke Journal 2020; 2 (1): 1002 (1-5). Published Date: May 06, 2020. 10.5281/zenodo.3887478

-Al-Mosawi AJ. The use of piracetam and cerebrolysin in the treatment of agenesis of corpus callosum with colpocephaly. EC clinical and medical case reports 2020; 3(1): 01-05.

-Al-Mosawi AJ. Wohlfart Kugelberg Welander syndrome. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-9-84548-4).

-Al-Mosawi AJ. The use of cerebrolysin in pediatric Wohlfart Kugelberg Welander syndrome. MOJ Clinical & Medical Case Reports (e-ISSN: 2381-179X) 2020; 10(1):20-23. DOI: 10.15406/mojcr.2020.10.00335

-Al-Mosawi AJ. A novel therapy for pediatric Charcot Marie Tooth disease. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-8-39043-5).

-Al-Mosawi AJ. The use of Cerebrolysin in Pediatric Charcot Marie Tooth 18-Disease. Journal of neurological research and therapy2020; 3(2):17-21. DOI: 10.14302/issn.2470-5020.jnrt-20-3226.

-Al-Mosawi AJ. New medical therapies for the treatment of myelomeningocele. Surgical Medicine Open Access Journal (ISSN: 2578-0379) 2019; 2(4): 1-4.

-Al-Mosawi AJ. A novel therapeutic approach for idiopathic mental retardation. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-9-81808-2).

-Al-Mosawi AJ. Unique experience with mental and developmental retardation: Innovative Medical therapies for idiopathic mental retardation. EC Clinical and Medical Case Reports 2020; 3(5): 42-54. Published: April 13, 2020. Doi: 10.5281/zenodo.3892214

-Al-Mosawi AJ. Clinical uses of cerebrolysin in pediatric neuropsychiatry. Science World Journal of Pharmaceutical Sciences 2020; 1(1):1-4. Published Date: 05 February 2020. Doi: 10. 5281/ zenodo.3878485

-Al-Mosawi AJ. The experience with the use of nandrolone decanoate and pyritinol in children with cerebral palsy. Open Access Journal of Biogeneric Science and Research (ISSN: 2692-1081) 2020; 2(3):1-3. Doi: 10.46718 / JBGSR.2020.01.000051

-Al-Mosawi AJ. Experience with refractory vitamin D-resistant rickets and non-17α alkyl testosterone derivative anabolic agent. Therapy (Clinical practice) [p-ISSN: 2044-9038, e-ISSN: 2044-9046] 2005; 2 (1):91-94. Doi: 10.2217/14750708.2.1.91

-Al-Mosawi AJ. The dramatic effect of non-17 alpha alkyl testosterone derivative anabolic agent on growth in a child with achondroplasia on the short term. Therapy (Clinical practice) [p-ISSN: 2044-9038, e-ISSN: 2044-9046 2006:3(5): 605-607.doi:10.2217/14750708.3.5.605

Published
2020-09-07
How to Cite
1.
Al-Mosawi AJ. Cerebral palsy: A unique illustrated experience: Cerebral palsy: A unique illustrated experience. Med. res. chronicles [Internet]. 2020Sep.7 [cited 2020Sep.24];7(4):217-39. Available from: https://medrech.com/index.php/medrech/article/view/441
Section
Original Research Article